2.23
0.09 (4.21%)
| Previous Close | 2.14 |
| Open | 2.04 |
| Volume | 34,494 |
| Avg. Volume (3M) | 86,242 |
| Market Cap | 33,444,436 |
| Price / Sales | 256.05 |
| Price / Book | 2.36 |
| 52 Weeks Range |
| Operating Margin (TTM) | -37,468.63% |
| Diluted EPS (TTM) | 3.38 |
| Quarterly Revenue Growth (YOY) | -51.70% |
| Quarterly Earnings Growth (YOY) | -19.50% |
| Total Debt/Equity (MRQ) | 26.43% |
| Current Ratio (MRQ) | 2.45 |
| Operating Cash Flow (TTM) | -19.88 M |
| Levered Free Cash Flow (TTM) | -11.33 M |
| Return on Assets (TTM) | -135.82% |
| Return on Equity (TTM) | -485.36% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Serina Therapeutics, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 2.0 |
| Average | 0.38 |
|
Serina Therapeutics, Inc. operates as a pharmaceutical company that develops drugs to treat neurological diseases, cancer, and pain. The company develops a pipeline of partnered programs applying POZ platform to cancer, pain, refractory epilepsy, and movement disorders, such as Parkinson's disease and restless leg syndrome. Its pipeline includes SER-214, a solution for Parkinson's disease/restless leg syndrome; SER-226, a post-operative pain management solution; SER-228 for refractory epilepsy; SER-232 for chemotherapy-induced nausea and vomiting; and polymer poly (2-oxazoline) or POZ drug delivery polymer technology. Serina Therapeutics, Inc. was incorporated in 2006 and is based in Huntsville, Alabama. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 63.85% |
| % Held by Institutions | 3.37% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Keel Point, Llc | 31 Mar 2026 | 21,508 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |